Literature DB >> 10460626

Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.

K Schmitz, W Brugger, B Weiss, E Kaiserling, L Kanz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10460626     DOI： 10.1046/j.1365-2141.1999.01608.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity.

Authors:  Magdalena Winiarska; Dominika Nowis; Jacek Bil; Eliza Glodkowska-Mrowka; Angelika Muchowicz; Malgorzata Wanczyk; Kamil Bojarczuk; Michal Dwojak; Malgorzata Firczuk; Ewa Wilczek; Malgorzata Wachowska; Katarzyna Roszczenko; Marta Miaczynska; Justyna Chlebowska; Grzegorz Wladyslaw Basak; Jakub Golab
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

Review 2.  Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.

Authors:  Berna Bozkurt Duman; Berksoy Sahin; Melek Ergin; Birol Guvenc
Journal:  Med Oncol       Date:  2011-07-31       Impact factor: 3.064

3.  Relapsed disease: off-the-shelf immunotherapies vs customized engineered products.

Authors:  Reem Karmali
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Rituximab maintenance in indolent lymphoma: indications and controversies.

Authors:  Marinus H J van Oers
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

5.  Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Takaaki Hato; Jun Yamanouchi; Tatsushiro Tamura; Norimasa Hojo; Yasunari Niiya; Masashi Kohno; Shiro Bando; Yoshihiro Yakushijin; Kiyonori Takada; Ikuya Sakai; Masaki Yasukawa; Shigeru Fujita
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

6.  Re-treatment of relapsed indolent B-cell lymphoma with rituximab.

Authors:  T Igarashi; T Ohtsu; H Fujii; Y Sasaki; Y Morishima; M Ogura; Y Kagami; T Kinoshita; M Kasai; Y Kiyama; Y Kobayashi; K Tobinai
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.319

7.  Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.

Authors:  Magdalena Winiarska; Kamil Bojarczuk; Beata Pyrzynska; Jacek Bil; Marta Siernicka; Michal Dwojak; Malgorzata Bobrowicz; Nina Miazek; Piotr Zapala; Agnieszka Zagozdzon; Magdalena Krol; Aleksandra Syta; Paulina Podszywalow-Bartnicka; Zofia Pilch; Anna Dabrowska-Iwanicka; Przemyslaw Juszczynski; Dimitar G Efremov; Mikolaj Slabicki; Thorsten Zenz; Aude Le Roy; Daniel Olive; Tomasz P Rygiel; Jeanette H W Leusen; Jakub Golab
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

Review 8.  Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.

Authors:  Kensei Tobinai
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.319
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.